Mark S. Levine - Feb 22, 2024 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Role: Chief Legal Officer
Signature: /s/ Eva Renee Barnett, attorney-in-fact for Mark S. Levine
Stock symbol: IMVT
Transactions as of: Feb 22, 2024
Transactions value $: -$77,144
Form type: 4
Date filed: 2/23/2024, 04:18 PM
Previous filing: Jan 29, 2024
Next filing: Apr 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMVT	Common Stock	Sale	-$77.1K	-2.13K	-0.7%	$36.15	302K	Feb 22, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on February 17, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
F2	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.85 - $36.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Content

On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on February 17, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.85 - $36.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.